AR072544A1 - Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno - Google Patents

Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno

Info

Publication number
AR072544A1
AR072544A1 ARP090102452A ARP090102452A AR072544A1 AR 072544 A1 AR072544 A1 AR 072544A1 AR P090102452 A ARP090102452 A AR P090102452A AR P090102452 A ARP090102452 A AR P090102452A AR 072544 A1 AR072544 A1 AR 072544A1
Authority
AR
Argentina
Prior art keywords
progestogen
delivery system
suppress abnormal
contraception
drug
Prior art date
Application number
ARP090102452A
Other languages
English (en)
Inventor
Heikki Lyytikaeinen
Satu Kleemola
Bernd Duesterberg
Manja Ahola
Jyrki Pihlaja
Harri Jukarainen
Tero Parkatti
Original Assignee
Bayer Schering Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40020198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072544(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Oy filed Critical Bayer Schering Pharma Oy
Publication of AR072544A1 publication Critical patent/AR072544A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Communication Control (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Método mejorado para anticoncepcion, para evitar o suprimir el sangrado endometrial anormal y/o irregular y para lograr una rápida induccion de la amenorrea, utilizando un sistema de suministro intrauterino que comprende un progestágeno - o una droga que tiene una actividad progestagénica - para liberacion controlada durante un período prolongado - y a un nivel terapéutico requerido para la anticoncepcion - y una cantidad suficiente de una o más sustancias terapéuticamente activas con la capacidad de suprimir el sangrado endometrial anormal y/o irregular. Uso, Progestágeno. Reivindicacion 5: Un método de acuerdo con la reivindicacion 4, caracterizado porque el progestágeno - o una droga que tiene una actividad progestagénica - es levonorgestrel. Reivindicacion 7: Un método de acuerdo con la reivindicacion 6, caracterizado porque la sustancia terapéuticamente activa con la capacidad de evitar o suprimir el sangrado endometrial anormal y/o irregular es el ácido tranexámico, el ácido mefenámico, danazol o un inhibidor de angiogénesis. Reivindicacion 13: Un sistema de suministro intrauterino para la liberacion controlada de progestágeno - o una droga que tiene una actividad progestagénica - durante un periodo prolongado y a un nivel requerido para la anticoncepcion, en el cual el sistema de suministro intrauterino comprende una estructura de un cuerpo y al menos un deposito que comprende un nucleo y - opcionalmente - una membrana que reviste el nucleo, el nucleo y la membrana consisten esencialmente en una composicion polimérica igual o diferente, caracterizado porque dicho sistema de suministro intrauterino comprende, adicionalmente, al menos una sustancia terapéuticamente activa con la capacidad de evitar o suprimir el sangrado endometrial anormal y/o irregular.
ARP090102452A 2008-07-03 2009-07-01 Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno AR072544A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08397516A EP2140860A1 (en) 2008-07-03 2008-07-03 An improved method of contraception

Publications (1)

Publication Number Publication Date
AR072544A1 true AR072544A1 (es) 2010-09-08

Family

ID=40020198

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102452A AR072544A1 (es) 2008-07-03 2009-07-01 Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno

Country Status (22)

Country Link
US (3) US20110146693A1 (es)
EP (3) EP2140860A1 (es)
JP (3) JP2011526609A (es)
KR (2) KR20110026516A (es)
CN (2) CN102088954A (es)
AR (1) AR072544A1 (es)
CA (1) CA2730040A1 (es)
CL (1) CL2009001490A1 (es)
CY (1) CY1120878T1 (es)
DK (1) DK2905014T3 (es)
ES (1) ES2673154T3 (es)
HR (1) HRP20180869T1 (es)
HU (1) HUE037520T2 (es)
LT (1) LT2905014T (es)
PE (1) PE20100057A1 (es)
PL (1) PL2905014T3 (es)
PT (1) PT2905014T (es)
SI (1) SI2905014T1 (es)
TR (1) TR201807996T4 (es)
TW (2) TW201002288A (es)
UY (1) UY31957A (es)
WO (1) WO2010000943A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031902A1 (en) 2008-09-17 2010-03-25 Bayer Schering Pharma Oy An inserter
FI20080524A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
FI20080523A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
WO2012121811A1 (en) * 2011-03-04 2012-09-13 Arstat, Inc. Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
SE539540C2 (sv) 2013-09-12 2017-10-10 Qpharma Ab Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar
AU2014336286A1 (en) * 2013-10-18 2016-03-24 Bayer Oy Intrauterine delivery system
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2015189853A1 (en) 2014-06-13 2015-12-17 Meril Endo Surgery Private Limited An intrauterine device
TWI730948B (zh) * 2014-12-08 2021-06-21 芬蘭商拜耳股份有限公司 新穎的熱塑性聚胺甲酸酯，彼等材料於製造子宮內系統之ｔ-框架之用途及由此等材料製成之ｔ-框架
JP6756718B2 (ja) * 2015-01-21 2020-09-16 バイエル・オサケユキテュアＢａｙｅｒ Ｏｙ 非ステロイド性抗炎症薬（ｎｓａｉｄ）およびプロゲストゲン化合物を含む薬剤送達システムならびに製造するための方法
US20180140640A1 (en) 2015-04-22 2018-05-24 Cadens Beheer B.V. Improved contraceptive methods and compositions and devices for use therein
EP3294300A1 (en) 2015-05-13 2018-03-21 Bayer Oy A long acting drug delivery device and its use in contraception
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP6936801B2 (ja) * 2015-12-21 2021-09-22 バイエル・オーイュー 薬剤送達装置の製造方法およびその方法に従って製造された薬剤送達装置
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB2555373A (en) * 2016-08-23 2018-05-02 Reproductive Medicine And Gynaecology Associates Ltd Implant
AU201617347S (en) * 2016-12-23 2017-01-23 Jurox Pty Ltd intravaginal device
JOP20200067A1 (ar) * 2017-09-27 2020-04-27 Bayer Oy طريقة لتعديل اطلاق عامل فعال علاجياً من مادة أساس لدنة
CN111770750B (zh) 2017-12-22 2024-05-10 阿利拉生物科技有限公司 痛经有关的疼痛和/或疼痛相关症状的治疗
KR20210129687A (ko) * 2019-02-22 2021-10-28 엘켐 실리콘즈 유에스에이 코포레이션 활성 성분 용출을 개선시키기 위한 약물 전달 실리콘 조성물
US20200268932A1 (en) * 2019-02-22 2020-08-27 Arsenal Aaa, Llc. Crosslinkable polymer compositions
KR102260999B1 (ko) * 2019-03-27 2021-06-04 (주)엠케어코리아 난소암 검사용 임플란트 및 이를 포함하는 검사킷 및 이를 이용한 난소암 검사방법
CN110215447A (zh) * 2019-06-14 2019-09-10 上海市计划生育科学研究所 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物
WO2021102220A1 (en) 2019-11-21 2021-05-27 Coopersurgical, Inc. Packaging systems for implantable devices and related methods
CN116807727B (zh) * 2023-08-29 2023-11-21 上海宇度医学科技股份有限公司 一种妇产科医师用临床取环器

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US4188951A (en) 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4495934A (en) 1978-07-25 1985-01-29 Shaw Jr Seth T IUD Arrangement
US4284074A (en) * 1978-07-26 1981-08-18 Shaw Jr Seth T IUD Arrangement
AU538963B2 (en) 1979-07-09 1984-09-06 Seth Thomas Shaw Jr. Drug for use with an iud
FR2539027B1 (fr) 1983-01-07 1987-03-06 Levrier Marc Systeme endo-uterin contraceptif et therapeutique associant cuivre, argent, hormone naturelle et acide iso amino caproique
NL8603216A (nl) * 1986-12-17 1988-07-18 Kurz Karl Heinz Inrichting om in de uterus te plaatsen.
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
FI94947C (fi) 1994-04-05 1995-11-27 Maillefer Nokia Holding Sovitelma lankamaisia tuotteita puolaavan koneen yhteydessä
FI97944C (fi) * 1994-07-05 1997-03-25 Leiras Oy Vaikuttavaa ainetta luovuttava laite
FI97947C (fi) 1994-09-27 1997-03-25 Leiras Oy Menetelmä lääkepreparaatin valmistamiseksi
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
EP0944382A1 (en) 1996-09-30 1999-09-29 Brigham & Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
FI103051B (fi) 1997-08-22 1999-04-15 Schering Oy Uusia blokkikopolymeerejä ja niiden valmistus
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
WO2002038159A1 (fr) * 2000-11-10 2002-05-16 Mitsubishi Pharma Corporation Medicaments pour l'hyperplasie endometriale
WO2003017971A1 (en) * 2001-08-31 2003-03-06 Schering Oy Drug delivery system
JP2003221338A (ja) * 2002-01-29 2003-08-05 Masao Igarashi 子宮腺筋症治療製剤
EP1620060B1 (en) * 2003-04-29 2010-03-24 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
WO2006028431A1 (en) 2003-05-21 2006-03-16 Impres Medical, Inc. Intrauterine implant and methods of use
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
FI123188B (fi) * 2005-04-05 2012-12-14 Bayer Oy Ultraäänellä havaittavissa oleva kohdunsisäinen järjestelmä
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
CN100441156C (zh) * 2006-09-30 2008-12-10 华中科技大学 一种复合材料宫内节育器

Also Published As

Publication number Publication date
CL2009001490A1 (es) 2010-08-06
KR101659530B1 (ko) 2016-09-23
EP2140860A1 (en) 2010-01-06
CA2730040A1 (en) 2010-01-07
HRP20180869T1 (hr) 2018-08-24
LT2905014T (lt) 2018-07-10
TW201002288A (en) 2010-01-16
EP2905014B1 (en) 2018-04-25
US9999592B2 (en) 2018-06-19
US10532025B2 (en) 2020-01-14
US20140127280A1 (en) 2014-05-08
CY1120878T1 (el) 2019-12-11
TW201601699A (zh) 2016-01-16
EP2905014A1 (en) 2015-08-12
EP2313084A1 (en) 2011-04-27
JP2016166245A (ja) 2016-09-15
JP2011526609A (ja) 2011-10-13
ES2673154T3 (es) 2018-06-20
JP2014129412A (ja) 2014-07-10
WO2010000943A1 (en) 2010-01-07
EP2313084A4 (en) 2014-03-05
KR20150136143A (ko) 2015-12-04
US20180263899A1 (en) 2018-09-20
JP6008893B2 (ja) 2016-10-19
DK2905014T3 (en) 2018-06-25
TWI602556B (zh) 2017-10-21
HUE037520T2 (hu) 2018-09-28
CN103976816A (zh) 2014-08-13
CN102088954A (zh) 2011-06-08
UY31957A (es) 2010-01-29
SI2905014T1 (en) 2018-08-31
US20110146693A1 (en) 2011-06-23
PT2905014T (pt) 2018-06-22
PL2905014T3 (pl) 2018-10-31
TR201807996T4 (tr) 2018-06-21
PE20100057A1 (es) 2010-02-25
KR20110026516A (ko) 2011-03-15

Similar Documents

Publication Publication Date Title
AR072544A1 (es) Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno
PE20110573A1 (es) Sistema de administracion de drogas que contiene progestina
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
AR065039A1 (es) Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
GT201200281A (es) Formas de dosificación sólidas orales con dosis muy bajas para la hrt
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
BRPI0518282A2 (pt) uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
AR064014A1 (es) Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
PE20081361A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
PE20060127A1 (es) Sistema de entrega de farmacos constituido por copolimero de polietileno acetato de vinilo
DOP2010000253A (es) Sistema de administracion de drogas con efecto estabilizante
BRPI0713257B8 (pt) sistema terapêutico transdérmico para a aplicação de norelgestromina
NZ604342A (en) Antipsychotic injectable depot composition
PE20160534A1 (es) Sistema de administracion intrauterina
AR084707A1 (es) Una composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociados al sistema cardiovascular
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR089765A1 (es) Un sistema para el suministro de un farmaco
BRPI0518062A (pt) uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
UY31343A1 (es) Composicion con una combinacion de principios activos para el tratamiento del estrenimiento
AR070375A1 (es) Sistemas de administracion de drogas que contienen estradiol
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Legal Events

Date Code Title Description
FC Refusal